# NCT03725059 (NCT03725059)

> Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03725059
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Breast Cancer
- Interventions: Pembrolizumab (K); Placebo (P); Paclitaxel (X); Doxorubicin (A); Epirubicin (E); Cyclophosphamide (C); Endocrine therapy; Radiation therapy; Surgery
- Enrollment: 1240
- Primary outcome: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
- Primary outcome: Event-Free Survival (EFS)

## Commentary we found

- YouTube: 49
- Podcasts: 45
- X threads: 40

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03725059

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03725059", "email": "<work email>"}; the inbox owner confirms by the emailed link.